US estrogen supply crunch widens as women seek alternatives to scarce patches
US women face shortages of estrogen patches, injectables, and vaginal creams due to surging demand. The FDA has been working with manufacturers to boost supplies since September. Companies like Viatris, Amneal, and Cost Plus Drugs report increased demand and production efforts. Shortages may be exacerbated by women switching from scarce patches to alternatives. Multiple manufacturers, including Hikma, American Regent, and Teva, are affected.
How this was made
The 30-second read
Why it matters
Supply constraints across multiple manufacturers may create pricing power for those able to meet demand, while companies struggling to scale could see margin pressure.
Market read
Shortages in hormone replacement therapy products could affect stock prices of listed manufacturers, with potential upside for those expanding capacity.
What to watch
Regulatory actions or raw material constraints could limit capacity expansions despite company statements.
Background
U.S. women face shortages of estrogen patches, injections, and creams after FDA removed a boxed warning, spurring demand.
Ticker impact
Viatris reports a surge in demand and increased production for estradiol patches and creams amid nationwide shortages.
upward pressure as the market prices in higher sales from shortage-driven demand
Company is expanding capacity and sees strong demand; shortages typically support higher pricing and volume.
Teva is listed among manufacturers with estradiol products on backorder or allocation due to supply constraints.
moderate upside as investors anticipate higher pricing power from limited supply
Shortages often translate into better pricing for the affected product lines.
Amneal, another estradiol patch maker, reports rising demand and plans to increase production.
upward pressure from anticipated revenue growth
Company is actively expanding capacity, but scale of impact is uncertain.
Market effects
Potential boost for the broader hormone replacement therapy sector as shortages may raise prices.
U.S. pharmaceutical supply chain concerns could affect related healthcare stocks.
Limited to U.S. market; no immediate global macro effect.
Counterpoint
If shortages persist, competitors may lose market share to firms that can meet demand, but higher costs could hurt margins.
Key entities
- companyViatris
Manufacturer of estradiol patches and creams expanding production.
- companyTeva Pharmaceutical Industries
Manufacturer of estradiol products on backorder.
- companyHikma Pharmaceuticals
Supplier of estradiol injection products facing shortages.
- companyAmneal Pharmaceuticals
Estradiol patch maker increasing production amid demand surge.
